Natco Pharma Ltd.

NATCO Pharma is currently trading at Rs. 492.65, up by 24.60 points or 5.26% from its previous closing of Rs. 467.40 on the BSE.

The scrip opened at Rs. 477.45 and has touched a high and low of Rs. 496.00 and Rs. 477.45 respectively. So far 50,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 496.00 on 10-Dec-2012 and a 52 week low of Rs. 223.50 on 20-Dec-2011.

Last one week high and low of the scrip stood at Rs. 476.70 and Rs. 462.00 respectively. The current market cap of the company is Rs. 1,532 crore.

The promoters holding in the company stood at 57.05% while Institutions and Non-Institutions held 17.88% and 25.07% respectively.

NATCO Pharma has received approval from the US Food & Drug Administration (USFDA), of its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed Release Capsules, USP, 15 mg and 30 mg for the prescription market. The shipments of this product will commence immediately.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.